A Retrospective Real-World Study Based on RATIONALE-307
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
About this trial
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Disqualifiers
Patients who had a documented death before study completion in the RATIONALE-307 trial
Trial population
Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
No intervention
Other interventionNo intervention
Treatment groups
109 Participants
are divided into 1 treatment groupGroup A: Extension Cohort1 intervention
Trial outcomes
Primary outcomes
1
Overall Survival (OS)
Time frame
Defined as the time from the date of randomization in the RATIONALE-307 trial to the date of death from any cause occurring on or before December 31, 2025.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov